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Abstract Stroke continues to be a serious and significant
health problem in the USA and worldwide. This article will
emphasize the need for good laboratory practices, transparent
scientific reporting, and the use of translational research mod-
els representative of the disease state to develop effective
treatments. This will allow for the testing and development
of new innovative strategies so that efficacious therapies can
be developed to treat ischemic and hemorrhagic stroke. This
article recommends guidelines for effective translational re-
search, most importantly, the need for study blinding, study
group randomization, power analysis, accurate statistical anal-
ysis, and a conflict of interest statement. Additional guidelines
to ensure reproducibility of results and confirmation of effi-
cacy in multiple species are discussed.
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“We can’t solve problems by using the same kind of
thinking we used when we created them.”
Albert Einstein (German born American Physicist.
1879–1955)
Translational Research is Key to Drug Development
Success
There remains a critical medical need for new therapeutic
strategies to treat acute ischemic stroke (AIS) and hemorrhage
stroke, including subarachnoid hemorrhage (SAH) and intra-
ventricular hemorrhage (IVH), to improve the quality of life
for stroke victims. This article will emphasize the need for
good laboratory practices, transparent scientific reporting, and
the use of translational research models representative of the
disease state, with bonafide clinically relevant endpoints to
develop and test new innovative strategies so that efficacious
therapies can be developed to treat stroke, which remains a
serious and significant health problem. According to the US
stroke statistics, each year, approximately 795,000 victims
suffer a new or recurrent stroke, 75 % of which are first
strokes. Eighteen percent of stroke victims (143,100) die from
the brain attack. AIS is now the fourth leading cause of death
and the leading cause of adult disability in the USA with an
estimated cost range of $69–74 billion annually [1–3], a cost
that continues to increase due to the high cost of medical
insurance plans and care in the USA. Currently, the only Food
and Drug Administration (FDA)-approved treatment for
stroke is the thrombolytic tissue plasminogen activator (tPA)
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if administered within 3 h of a stroke. However, the clot-
busting drug therapeutic window has been expanded and has
been shown to be beneficial if given 3–6 h after a stroke [4–6].
Although thrombolysis is now widely accepted as a standard
of care for AIS, only a minority (5 %) of AIS patients are
treated with tPA in the USA [7].
Importantly, a recent cost-effectiveness survey based up-
on the utilization of tPA, the only FDA-approved treatment
for AIS [3] within 3–4.5 h after stroke onset, clearly showed
that in AIS patients with National Institutes of Health Stroke
Scale (NIHSS) scores of 0–19, there was an incremental
benefit to the patient administered with tPA compared to
patients with no treatment. Thus, there was benefit in terms
of quality-adjusted life-years. However, interestingly, the
analysis showed reduced benefit in patients with an NIHSS
score >19, and there was no benefit in diabetic patients or
patients with atrial fibrillation. Information gained from the
repeated testing of tPA [4, 8], and subsequent population
analyses should be incorporated into current and future
translational development programs.
“The true sign of intelligence is not knowledge but
imagination.”
Albert Einstein (German born American Physicist.
1879–1955)
It is clear that without rigorous translational research,
which is based upon incremental prior knowledge, progress
cannot be made. The basis for future translational research
should incorporate novel ideas and a series of specified
guidelines to increase the possibility of success in clinical
trials and in the open heterogeneous patient population after
the FDA approval process.
A Brief Chronological History of Stroke
Historically, stroke, or a condition referred to as apoplexy, or
the sudden onset of paralysis was first “reported” by Hippo-
crates over 2,400 years ago between 460 and 370 BC and
can be found in Hippocratic transcripts [9]. In the mid to late
1500 s through the early 1600 s, there were many descrip-
tions of apoplexy (apoplectic seizure) by Wepfer who cor-
rectly presented a realistic classification of apoplexy into
hemorrhagic stroke and cerebral infarction in 1658 [10]. The
fascinating account by Wepfer, discussed in detail by Gurd-
jian and Gurdjian [11], recounts the idea that body-derived
“natural spirits” which become “vital spirits” are transported
into the brain via the carotid and verterbal arteries and a
network of arteries at the base of the brain (i.e., circle of
Willis), which was quite elegantly described by Thomas
Willis in the mid 1600 s [12]. So that the concept is not lost
in translation, Wepfer’s suggestion implied that oxygenated
blood was transported into the brain as a vital factor, as a
source of nutrition, and Willis suggested that our current
concept of the “cerebrovascular system” included a network
of arteries, including the “circle of Willis”.
Autopsy records from the 1700 s confirmed two types of
apoplexy, suggested to be serous apoplexy (apoplexia serosa)
and sanguineous apoplexy (apoplexia sanguinea). Between the
early 1600 s and themid 1800 s, the 1866writings of Dechambre
summarized over 150 apoplexy references [13]. Subsequently, in
1856, Virchow [14] was the first physician to recognize that an
embolus could result in a thromboembolism, and coined the
terms related to the pathogenesis of ischemic stroke. In the more
recent literature, Bramwell and Symonds published articles in
1886 [15] and 1924 [16], respectively, describing the “spontane-
ous” meningeal and SAH. It is now known that brain hemor-
rhage, SAH, ICH, and IVH occur in approximately 17–20 % of
all patients with a stroke [1, 2, 17]. Hemorrhage is associated
with a rapid decline and higher mortality rate than ischemic
stroke. The 30-day mortality rate for ischemic stroke is estimated
to be 8–12 %, whereas hemorrhagic stroke is estimated to be 5
0 % [18–21]. Both conditions are in dire need of treatment.
“If at first, the idea is not absurd, then there is no hope
for it”
Albert Einstein (German born American Physicist.
1879–1955)
Translational Stroke Research
The promise that translational studies will offer potentially
significant treatment of AIS has still not been realized due to
the lack of efficacy of neuroprotectants in randomized clinical
trials, thus, the FDA has not approved any neuroprotectant
strategy to treat stroke [22–25]. Moreover, neurorestorative
molecules and stem cells that may promote recovery of func-
tion have not been developed to a point where they have been
adequately tested in clinical trials, although this is a strategy
where attention is justified [23, 25–27].
The Status of STAIR
In 1999, the original set of stroke therapy academic industry
roundtable (STAIR) recommendations, which resulted from a
collaborative effort between academics and industry [28],
documented a series of basic criteria or primary recommenda-
tions that should be followed to advance the field of stroke
research. The STAIR report only addressed rodent and primate
studies and their utility to measure at least two outcomes,
functional response and infarct volume in the acute stroke
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phase (1–3 days) and thereafter (7–30 days). In contrast to
STAIR, the report by Sharp and colleagues [29] emphasized
the utility of the non-rodent species, Oryctolagus cuniculus
(rabbit), to develop stroke therapies because of the track record
and historical significance of the model in the preclinical
development of tPA (see [22, 29] for references and discussion
on this topic). The reader is also referred to a recent article by
Cook and Tymianski that attempts to provide additional justi-
fication for the use of nonhuman primates to bridge the trans-
lational gap between animals and humans [30].
STAIR 1 also recommended the following:
1. Randomized and blinded studies
2. Efficacy in two or more laboratories
3. Replication in a second species
4. Consideration of sex difference
5. Consideration of route of administration (to administer
intravenous or not)
6. Consideration of a clinically useful therapeutic window
and dose response
From 2004 to 2011, STAIR continued to report on recom-
mendations for developing neuroprotective therapies, expand-
ing treatment options, utilizing combination therapies and
designing clinical trials [31–34]. The recommendations
attempted to address the problems resulting from the devas-
tating failure of NXY-059 [35]. While NXY-059 was deemed
an acceptable but not optimal development plan [36–40], by
original STAIR criteria, retrospective analysis showed that its
beneficial effects were over estimated in preclinical studies
[36]. Thus, even though these new criteria were put into place,
subsequent clinical trials, relying on this more stringent
development criteria, failed to produce any benefit.
The 2009 STAIR report [33] included updated recommen-
dations related to the conduct of good science or good labo-
ratory practice. The most important aspects are the following:
1. Eliminating randomization and assessment bias
2. Defining inclusion/exclusion criteria
3. Conducting full power analysis and sample size
calculations
4. Disclosing potential conflicts of interest
The recommendations also attempted to address comor-
bidities that are commonly recognized in stroke patients and
the need for inclusion of those comorbidities in preclinical
investigations. Thus, the following STAIR suggestion was
made: “after initial evaluations in young, healthy male
animals, further studies should be performed in females,
aged animals, and animals with co-morbid conditions such
as hypertension, diabetes, and hypercholesterolemia”. This
is a recommendation for the use of an extensive number of
animal models for future translational studies, in an attempt
to effectively translate preclinical studies into the clinic,
even though the development process for a neuroprotective
has still not been validated by a “positive” clinical trial.
Nevertheless, understandably, the recommendation was
centered around the idea that studies in animal models with
comorbidities would better reproduce the “pathophysiolog-
ical” state of patients presenting with strokes, but, clearly,
this may not be the case due to the observations made below.
Using the National Institure of Neurological Disorders and
Stroke (NINDS) rt-PA and ECASSIII trials as examples, the
stroke patient population had the characteristics described in
Table 1. The most pertinent aspects are that strokes occur in a
mixed gender aged population, particularly those with a his-
tory of hypertension or diabetes, which is usually controlled
by one or more pharmaceuticals. Moreover, the majority of
stroke patients are not antihypertensive-naive [41, 42], and
may receive anticoagulants and statins [41]. These points are
important when considerations are made regarding the use of a
“correct” animal model for drug development.
There is also significant information available in the liter-
ature regarding the group of refractory diabetic patients en-
rolled in the NINDS rt-PA trial [8] and the ECASS III trial [4],
which includes a small percentage of patients with diabetes
(Table 1). It is extremely difficult to treat diabetic stroke
patients since they do not respond [3] or have an attenuated
response to standard dose thrombolytic therapy [43–45].
Patients with diabetes have been shown to be independently
associated with poor neurological outcome and higher mor-
tality in the absence of thrombolytic treatment [43–45], and
among patients treated with intravenous tPA [8], the presence
of diabetes significantly reduces the odds of favorable out-
come at 3 months [17].
Considering the information provided above and the
refractory phenomenon in diabetic patients, will using a
standard naive-hypertensive rodent be sufficient to predict
drug efficacy in a heterogeneous population of stroke
patients? Should translational studies attempt to address
the diabetic population presenting with a stroke, or should
Table 1 Stroke patient characteristics
Characteristic NINDS rt-PA(8) ECASS III(4)
Age (years) >66 >64.9
Gender (% male) 57–60 57.3–63.2
Mean NIHSS 10.7–11.6
Hypertension (%) 64–66 62.4–62.8
Diabetes (%) 20–24 14.8–16.6
Prior use of drugs (%)
Aspirin/antiplatelet 26–40 31.1–32.5
Tobacco (current) – 28.8–30.6
Tobacco (Ex-smoker) – 20.6–24.6
Tobacco (current or Ex-smoker) 27–43 –
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“proof of concept” efficacy first be obtained for the larger
mixed gender aged population, leaving clinical study in
diabetics for post FDA drug approval?
STEPS Toward a Stroke Therapy
The stem cell therapies as an emerging paradigm in stroke
(STEPS) investigative team has paralleled the STAIR com-
mittee by documenting recommendation for developing
stem cell therapy for stroke [46, 47]. STEPS is focused on
a cell-based restorative therapy, whether the mechanism of
action be central or peripheral, that may be independent of
cell access to the ischemic penumbra or core. Many of the
recommendation of STEPS are similar to STAIR recom-
mendations including:
1. Test therapy in multiple strains
2. Replication in a second species
3. Consideration of age and gender
4. Functional outcome (minimum of 1 month)
5. Consideration of a clinically useful therapeutic window
and dose response
6. Consideration of route of administration (intracerebral
or systemic)
7. Study ischemic and hemorrhagic stroke subgroups
The second STEPS report [47] added little to the first
report recommendations with respect to procedural issues,
with the following exceptions:
1. Reproducibility (confirmation) in multiple laboratories
and in two species
2. The possible addition of comorbidities (hypertensive,
diabetic)
3. “Positive, neutral, and negative” study outcomes should
be reported
The RIGORs of Stroke Drug Development
The NINDS sponsored workshop on Improving the Quality of
NINDS-Supported Preclinical and Clinical Research through
Rigorous Study Design and Transparent Reporting was held
in June, 2012 in Washington, DC [48]. The objective of the
workshop was to improve the rigorous of preclinical research
even though application of fundamental principles of experi-
mental design and transparency in reporting are currently the
standard of practice by the clinical research community.
Dr. Malcolm Macleod (Centre for Clinical Brain Sciences,
University of Edinburgh) presented a PowerPoint session that
is directly pertinent to translational stroke research (Please see
original articles for additional information [49, 50]). Citing the
Collaborative Approach to Meta-Analysis and Review of
Animal Data from Experimental Studies projects, Macleod
showed data to support the following conclusions:
1. Measured effect (improvement) was larger in studies
done by investigators when there was no randomization.
2. Measured effect (improvement) was larger in studies done
by investigators when there was no blinded assessment.
3. In stroke research, only 36 % of published studies
reported randomization.
4. In stroke research, only 29 % of published studies were
blinded.
5. Power analysis was only documented by 3 % of pub-
lished studies.
6. There was no significant association (r200.06) between
the quality of science and the impact factor of the journal.
7. There was no significant association (r200.004) be-
tween the quality of science and the number of citations
of a particular study.
8. A significant amount of unpublished negative or neutral
data cause an overestimation of efficacy because of
published positive data.
Based upon the Macleod presentation and others based
upon the following criteria listed below, there were few
recurring themes for advancement of translational research,
which should be incorporated into translational grant appli-
cations and publications reporting translational research,
independent of the source of funding. This will ensure
reproducible, valid research on an international level.
1. Experimental design
(a) Rationale for the selected models and endpoints
(animal and/or cellular)
(b) Adequacy of the controls
(c) Route and timing of intervention delivery/dosing
(d) Justification of sample size, including power
calculation
(e) Statistical methods used in analysis and interpreta-
tion of results
For grant applications, the investigator must
present a solid and justified Experimental design
including full power analysis for the sample size to
be included in each experimental group. If there are
multiple endpoints to be measured, the investigator
should indicate how the study was powered and for
what specific endpoint. A recommendation is made
to present this information in manuscript submis-
sions for stroke-related journals including Transla-
tional Stroke Research.
2. Minimizing bias
(a) Methods of blinding (allocation concealment and
blinded assessment of outcome)
(b) Strategies for randomization and/or stratification
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(c) Reporting of data missing due to attrition or
exclusion
(d) Reporting of all results (negative and positive)
Macleod showed correlative data for greater
efficacy results when the investigator(s) were nei-
ther blinded or study randomized, thus reinforcing
the importance of adequate randomization and
blinding to minimize bias. This will require at least
one member of the experimental team to remain
naive to the study design, and the investigator
charged with drug administration cannot be the
person to randomize and blind the study. More-
over, to maintain blinding, the investigator respon-
sible for endpoint determination (i.e., behavioral
analysis) should be naive to the experimental
groups and order/randomization of drug adminis-
tration. A recommendation is made to use websites
such as http://randomizer.org/ to produce random-
ization tables for all groups to be included in the
study once power analysis for the number of ani-
mals per experiment (i.e., n or N) is established.
For all studies, the investigator is encouraged to
report to NIH in progress reports and in primary
scientific publications all data including missing
data due to attrition or exclusion, including techni-
cal complications.
3. Results
(a) Independent validation/replication, if available
(b) Robustness and reproducibility of the observed
results
(c) Dose–response and therapeutic window results
In translational grant applications with the spe-
cific aim of filing an IND application to initiate a
clinical trial, the investigator should incorporate
studies to replicate findings in a second external
laboratory and if possible, in a second species. This
strategy will ensure robust reproducible results. All
external studies should also be conducted in a
blinded and randomized manner. Standard good
laboratory practice should be followed for all phar-
macological studies using standard dose–response
analysis and therapeutic window analysis appropri-
ate for the condition to be treated.
4. Interpretation of results
(a) Alternative interpretations of the experimental data
(b) Discussion of effect size in relation to potential
clinical impact
(c) Potential conflicts of interest
While most pharmacological studies aimed at developing
a therapy are easily interpreted with a simplistic endpoint
that is being measured such as behavioral improvement or
infarct reduction, there are some instances where the inves-
tigator should be prepared to offer alternative explanations
of their results. For example, should reduced infarct volume
in a rodent model of embolic stroke, in the absence of
behavioral improvement significant, be used to establish
an IND? Alternatively, if there is significant behavioral
improvement without infarct volume reduction, can this
observation lead to a stroke clinical trial where NIHSS and
modified Rankin Scale are used as primary endpoints [4, 8,
35, 51–53]? The investigator should also incorporate a dis-
cussion of their findings in the context of the bigger picture
of the disease being studied, and whether their justified
endpoint is clinically relevant.
It’s not that I’m so smart, it’s just that I stay with
problems longer.
Albert Einstein (German born American Physicist.
1879–1955)
Conclusion
In conclusion, the following recommendations are made
to investigators interested in conducting translational
research using good laboratory practices. The RIGOR
guidelines discussed above, most importantly, method of
blinding, study group randomization, complete power
analysis and statistical analysis, should be incorporated
into translational grant applications and are recommen-
ded for all manuscripts submitted to Translational
Stroke Research. A conflict of interest statement is
required for all investigators on the study to include
all funding for the study, collaborations with the phar-
maceutical or biotechnology industry, scientific or clin-
ical advisory boards, and financial interest in the
industry broadly related to current work. It is recom-
mended that authors submitting articles to Translational
Stroke Research include a checklist (see Table 2) indi-
cating that the study was conducted using current
guidelines.
Table 2 Author RIGOR Criteria Adherence
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